Homo sapiens
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA97007 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:Gene expression analysis of gamma-secretase inhibitor-sensitive and -resistant T-ALL cell lines
| PRJNA96971 | ENA
Project description:The intramembrane protease gamma-secretase has broad physiological functions, but also contributes to Notch-dependent tumors and Alzheimer’s disease. To identify naturally short substrates and non-substrates of gamma-secretase, we used four human cell lines of different tissue origins, breast cancer MCF7 cells, cervix carcinoma HeLa cells, T cell leukemia Jurkat cells and lymphoma U937 macrophage-like cells. The cell lines were treated overnight with the established gamma-secretase inhibitor DAPT or DMSO as a control. The proteomes of membrane fractions were determined by nano-liquid chromatography-tandem mass spectrometry and label-free quantitative proteomics. TNFRSF12A, PTPRCAP and C16orf54 were identified as potential naturally short gamma-secretase substrates, whereas other proteins with a short ectodomain including ‘pituitary tumor-transforming gene 1-interacting protein’ (PTTG1IP) did not show an increased abundance upon DAPT treatment.
2024-05-24 | PXD045701 | Pride
Project description:Gene expression profiles of desmoid tumor cells treated with gamma-secretase inhibitor
| PRJNA260216 | ENA
Project description:This randomized phase I/II clinical trial is studying the side effects and best dose of gamma-secretase/notch signalling pathway inhibitor RO4929097 when given together with vismodegib and to see how well they work in treating patients with advanced or metastatic sarcoma. Vismodegib may slow the growth of tumor cells. Gamma-secretase/notch signalling pathway inhibitor RO4929097 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving vismodegib together with gamma-secretase/notch signalling pathway inhibitor RO4929097 may be an effective treatment for sarcoma.
| 2091475 | ecrin-mdr-crc
Project description:Analysis of five Notch signaling-dependent human T-ALL cell lines (ALLSIL, DND41, HPBALL, KOPTK1, TALL-1) treated with gamma-secretase inhibitor (GSI) to block Notch signaling. Samples include parental cells, cells rescued by retroviral transduction with ICN (a GSI-independent form of activated Notch1), and cells retrovirally transduced with c-Myc (an important downstream target of Notch1). Results allow segregation of bona fide Notch targets from other genes affected by gamma-secretase inhibition as well as from targets downstream of c-Myc. Thirty samples were analyzed. Five human T-ALL cell lines (ALLSIL, DND41, HPBALL, KOPTK1, TALL-1) were treated with gamma-secretase inhibitor (1.0 micromolar compound E) vs. DMSO vehicle control for 12 hours. Each cell line was also retrovirally transduced with ICN or c-Myc, FACS sorted, and then treated with GSI vs. DMSO.
2011-07-31 | E-GEOD-29959 | biostudies-arrayexpress
Project description:Gamma-secretase inhibitor plus fludarabine in CLL
| PRJNA219743 | ENA
Project description:Expression data from 3 gamma-secretase or mock-treated mantle cell lymphoma (MCL) cell lines
| PRJNA150467 | ENA
Project description:Analysis of five Notch signaling-dependent human T-ALL cell lines (ALLSIL, DND41, HPBALL, KOPTK1, TALL-1) treated with gamma-secretase inhibitor (GSI) to block Notch signaling. Samples include parental cells, cells rescued by retroviral transduction with ICN (a GSI-independent form of activated Notch1), and cells retrovirally transduced with c-Myc (an important downstream target of Notch1). Results allow segregation of bona fide Notch targets from other genes affected by gamma-secretase inhibition as well as from targets downstream of c-Myc.
2011-08-01 | GSE29959 | GEO
Project description:The mouse Ikaros-deficient thymic lymphoma cell line T29 was treated with a gamma-secretase inhibitor or vehicle (DMSO) for 36h and subjected to transcriptome analysis.
2013-04-17 | GSE46095 | GEO
Project description:We used DNA microarrays to compare RNA transcript expression from various glioma neurospheres after treatment with gamma-secretase inhibitor MRK003. Four glioma cell lines grown as neurospheres (GBM1, GBM2, GBM10 and GBM14) were treated two concentrations of with gamma-secretase inhibitor MRK003 (High and low dose, 0.4µM and 2.0µM respectively) and compared to vehicle (DMSO) control. Whole human genome gene expression was performed at the Johns Hopkins Oncology Microarray Core using 44k microarray technology (Agilent Technologies, CA, USA) according to manufacturer’s description including labeling, hybridization and detection. Gene annotation and expression analyses were performed using software packages available from the R/Bioconductor platform for statistical computing. In this series we provide raw expression data along with MIAME (Minimal Information about a Microarray Experiment).
2015-08-07 | E-GEOD-71769 | biostudies-arrayexpress